Results 131 to 140 of about 104,921 (341)

Drinking Tremor

Movement Disorders Clinical Practice, EarlyView.
Victor Rebelo Procaci, Lyamara Apostólico de Azevedo, Orlando Graziani Povoas Barsottini, Henrique Ballalai Ferraz, José Luiz Pedroso   +4 more
wiley   +1 more source

What Is Required for AI to Improve the Assessment and Treatment of Patients With Lower Urinary Tract Dysfunction? ICI‐RS 2025

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Artificial intelligence (AI) is poised to improve the diagnosis and management of lower urinary tract dysfunction (LUTD). Its effective deployment requires prioritization, regulatory oversight, rigorous validation, and clinician and patient engagement.
Glenn T. Werneburg, Michel Wyndaele, John E. Speich, Enrico Finazzi Agro, Mo Belal, Sachin Malde, George Bou Kheir, Emre Huri, Arjun K. Nambiar, Giovanni Mosiello, Riccardo Lombardo, Phil Toozs‐Hobson, Christopher R. Chapple, Alan J. Wein, Paul Abrams, Kevin Rademakers   +15 more
wiley   +1 more source

What Role Does the Central Nervous System Play in Refractory LUTS, and What Are the Therapeutic Implications? ICI‐RS 2025

Neurourology and Urodynamics, EarlyView.
ABSTRACT Aims While many patients with lower urinary tract symptoms (LUTS) improve by treating peripheral causes, a substantial proportion continue to experience symptoms despite apparently successful interventions. Central nervous system (CNS) mechanisms could potentially contribute to persisting symptoms after the initial peripheral cause has been ...
Mathijs M. de Rijk, Michel Wyndaele, Ana Charrua, Christopher Fry, Paul Abrams, Gommert A. van Koeveringe, Anthony J. Kanai, Marcus J. Drake   +7 more
wiley   +1 more source

POTILASOPAS BOTULIINITOKSIINIHOITOON TULEVALLE LAPSELLE [PDF]

, 2011
Opinnäytetyön tarkoituksena oli tehdä potilasopas botuliinitoksiinihoitoon tulevalle lapselle. Potilasopasta käytetään valmistaessa lasta tulevaan toimenpiteeseen sekä hoitoa antavassa yksikössä että kotona.
Koskinen, Saija, Virnes, Kirsi
core  

Effect of Intratrigonal Botulinum Toxin in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Long-Term, Single-Center Study in Real-Life Conditions [PDF]

, 2022
Pedro Abreu‐Mendes, António Ferrão-Mendes, Francisco Botelho, Francisco Cruz, Rui Pinto   +4 more
openalex   +1 more source

Save the Bladder: Continent Urinary Diversion as Best Practice for Patients With Refractory Neurogenic Lower Urinary Tract Dysfunction

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Refractory neurogenic lower urinary tract dysfunction presents an obstinate clinical problem. For patients who fail nonsurgical measures, we advocate for bladder‐sparing, continent urinary diversion as the optimal approach to management.
Brian W. Chao, Sean P. Elliott
wiley   +1 more source

Cosmetic use of botulinum toxin type A in the elderly

Clinical Interventions in Aging, 2007
Christine M ChengDepartment of Clinical Pharmacy, University of California, San Francisco, CA, USAAbstract: Botulinum toxin type A injections are one of the most popular cosmetic procedures for diminishing the appearance of facial lines caused by ...
Christine M Cheng
doaj  

From Toxin to Treatment: A Narrative Review on the Use of Botulinum Toxin for Autonomic Dysfunction

Toxins
Since its regulatory approval over a half-century ago, botulinum toxin has evolved from one of the most potent neurotoxins known to becoming routinely adopted in clinical practice.
Lucas Rempel, Raza N. Malik, Claire Shackleton, Martín Calderón-Juárez, Rahul Sachdeva, Andrei V. Krassioukov   +5 more
doaj   +1 more source

Phenotyping Overactive Bladder—Part 1: Are There Different Types of Urgency and Can They be Translated to Clinical, Urodynamic and Radiological Phenotyping? ICI‐RS 2025

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Overactive bladder (OAB) is defined as urinary urgency, usually accompanied by increased daytime frequency and/or nocturia, with urgency urinary incontinence (OAB‐wet) or without (OAB‐dry), in the absence of urinary tract infection or other detectable disease.
John E. Speich, D. Carolina Ochoa, Pradeep Tyagi, Apostolos Apostolidis, Sanjay Sinha, Claire Hentzen, Marcus Drake, Paul Abrams, Alan J. Wein, Michel Wyndaele   +9 more
wiley   +1 more source

Botulinum Toxin and Its Contribution to the Treatment of Masseteric Hypertrophy

Česká Stomatologie a Praktické Zubní Lékařství, 2005
With discovery and use of botulinum toxin masseteric hypertrophy has become treatable in a minimal invasive way. The authors discuss the masseteric hypertrophy as such as well as they describe a technique of clinical application of botulinum toxin in its
R. Jurkovič, P. Macák
doaj